10.48MMarket Cap-699P/E (TTM)
2.2000High2.0000Low132.07KVolume2.1900Open2.0200Pre Close280.73KTurnover2.65%Turnover RatioLossP/E (Static)4.99MShares3.330052wk High1.68P/B10.48MFloat Cap1.810052wk Low--Dividend TTM4.99MShs Float1419.0000Historical High--Div YieldTTM9.90%Amplitude1.5200Historical Low2.1250Avg Price1Lot Size
Can-Fite BioPharma Stock Forum
Rhe FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
NEWS
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
Moomoo 24/7· 1 min ago
GlobeNewswire· 3 mins ago
No comment yet